Forsta AP Fonden lowered its position in Humana Inc. (NYSE:HUM – Get Rating) by 9.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,500 shares of the insurance provider’s stock after selling 3,600 shares during the period. Forsta AP Fonden’s holdings in Humana were worth $14,578,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently added to or reduced their stakes in HUM. National Asset Management Inc. lifted its position in Humana by 5.0% in the fourth quarter. National Asset Management Inc. now owns 774 shares of the insurance provider’s stock valued at $359,000 after purchasing an additional 37 shares during the period. CWM LLC acquired a new stake in shares of Humana during the 4th quarter valued at approximately $218,000. Qube Research & Technologies Ltd lifted its position in shares of Humana by 113.3% during the 4th quarter. Qube Research & Technologies Ltd now owns 37,588 shares of the insurance provider’s stock valued at $17,436,000 after acquiring an additional 19,962 shares during the period. FDx Advisors Inc. acquired a new stake in shares of Humana during the 4th quarter valued at approximately $248,000. Finally, Fifth Third Bancorp lifted its position in shares of Humana by 6.6% during the 4th quarter. Fifth Third Bancorp now owns 9,695 shares of the insurance provider’s stock valued at $4,497,000 after acquiring an additional 602 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Humana from $450.00 to $514.00 in a research report on Thursday, July 28th. Morgan Stanley lifted their price target on shares of Humana from $453.00 to $494.00 and gave the company an “equal weight” rating in a research report on Tuesday. Oppenheimer lifted their price objective on Humana from $510.00 to $520.00 and gave the stock an “outperform” rating in a research report on Thursday, July 28th. Wells Fargo & Company lifted their price objective on Humana from $512.00 to $514.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 25th. Finally, SVB Leerink lifted their price objective on Humana from $535.00 to $540.00 and gave the stock an “outperform” rating in a research report on Thursday, July 28th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $508.61.
Humana Stock Up 0.9 %
Humana (NYSE:HUM – Get Rating) last released its earnings results on Wednesday, July 27th. The insurance provider reported $8.67 EPS for the quarter, topping the consensus estimate of $7.67 by $1.00. Humana had a net margin of 3.52% and a return on equity of 18.42%. The firm had revenue of $23.66 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the previous year, the company earned $6.89 EPS. Humana’s revenue for the quarter was up 14.6% on a year-over-year basis. As a group, sell-side analysts expect that Humana Inc. will post 24.85 EPS for the current year.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.